Table 3:
Serum levels of 25(OH)D and overall survivala among EA patients, stratified by clinical stage (N=476)
| 25(OH)D Quartilesb | N deaths/patients | HRc | 95% Confidence Limits | ||
|---|---|---|---|---|---|
| Lymph node negative at diagnosis | Quartile 1 (Highest) | 19/28 | REF | ||
| Quartile 2 | 21/41 | 0.93 | 0.49 | 1.76 | |
| Quartile 3 | 25/41 | 0.95 | 0.51 | 1.74 | |
| Quartile 4 (lowest) | 27/41 | 1.00 | 0.55 | 1.82 | |
| Lymph node positive at diagnosis | Quartile 1 (Highest) | 44/59 | REF | ||
| Quartile 2 | 39/57 | 0.95 | 0.61 | 1.47 | |
| Quartile 3 | 48/60 | 1.12 | 0.74 | 1.70 | |
| Quartile 4 (lowest) | 42/53 | 1.19 | 0.77 | 1.83 | |
| Metastatic at diagnosis | Quartile 1 (Highest) | 27/27 | REF | ||
| Quartile 2 | 22/22 | 0.80 | 0.45 | 1.42 | |
| Quartile 3 | 22/23 | 0.95 | 0.52 | 1.73 | |
| Quartile 4 (lowest) | 24/24 | 0.69 | 0.39 | 1.24 | |
a
Overall survival was calculated as time between date of blood draw and date of death or date last known to be alive.
b
Quartiles of vitamin D were determined accounting for month of blood draw.
c
Model adjusted for the main effect of vitamin D, age, sex, smoking status, the main effect of BMI categories, year of diagnosis, chemotherapy, radiation, time-dependent surgery, and baseline treatment, and baseline hazard was stratified by tumor stage by lymph node status.